271 related articles for article (PubMed ID: 11266468)
1. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies.
Bajou K; Masson V; Gerard RD; Schmitt PM; Albert V; Praus M; Lund LR; Frandsen TL; Brunner N; Dano K; Fusenig NE; Weidle U; Carmeliet G; Loskutoff D; Collen D; Carmeliet P; Foidart JM; Noël A
J Cell Biol; 2001 Feb; 152(4):777-84. PubMed ID: 11266468
[TBL] [Abstract][Full Text] [Related]
2. Plasmin-dependent and -independent effects of plasminogen activators and inhibitor-1 on ex vivo angiogenesis.
Brodsky S; Chen J; Lee A; Akassoglou K; Norman J; Goligorsky MS
Am J Physiol Heart Circ Physiol; 2001 Oct; 281(4):H1784-92. PubMed ID: 11557572
[TBL] [Abstract][Full Text] [Related]
3. Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice.
Swiercz R; Keck RW; Skrzypczak-Jankun E; Selman SH; Jankun J
Oncol Rep; 2001; 8(3):463-70. PubMed ID: 11295064
[TBL] [Abstract][Full Text] [Related]
4. Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis.
Leik CE; Su EJ; Nambi P; Crandall DL; Lawrence DA
J Thromb Haemost; 2006 Dec; 4(12):2710-5. PubMed ID: 17010152
[TBL] [Abstract][Full Text] [Related]
5. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent.
Devy L; Blacher S; Grignet-Debrus C; Bajou K; Masson V; Gerard RD; Gils A; Carmeliet G; Carmeliet P; Declerck PJ; Nöel A; Foidart JM
FASEB J; 2002 Feb; 16(2):147-54. PubMed ID: 11818362
[TBL] [Abstract][Full Text] [Related]
6. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin.
Arroyo De Prada N; Schroeck F; Sinner EK; Muehlenweg B; Twellmeyer J; Sperl S; Wilhelm OG; Schmitt M; Magdolen V
Eur J Biochem; 2002 Jan; 269(1):184-92. PubMed ID: 11784312
[TBL] [Abstract][Full Text] [Related]
7. [Role of PAI-1 plasminogen activator inhibitor in tumor invasion and angiogenesis].
Bajou K
Bull Mem Acad R Med Belg; 2002; 157(5-6):313-8. PubMed ID: 12557575
[TBL] [Abstract][Full Text] [Related]
8. Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.
Whitley BR; Church FC
Int J Oncol; 2005 Sep; 27(3):749-57. PubMed ID: 16077925
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells.
Chorostowska-Wynimko J; Swiercz R; Skrzypczak-Jankun E; Selman SH; Jankun J
Oncol Rep; 2004 Dec; 12(6):1155-62. PubMed ID: 15547731
[TBL] [Abstract][Full Text] [Related]
10. The Plasminogen-Activator Plasmin System in Physiological and Pathophysiological Angiogenesis.
Ismail AA; Shaker BT; Bajou K
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008762
[TBL] [Abstract][Full Text] [Related]
11. The urokinase receptor is a major vitronectin-binding protein on endothelial cells.
Kanse SM; Kost C; Wilhelm OG; Andreasen PA; Preissner KT
Exp Cell Res; 1996 May; 224(2):344-53. PubMed ID: 8612711
[TBL] [Abstract][Full Text] [Related]
12. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth.
Bajou K; Maillard C; Jost M; Lijnen RH; Gils A; Declerck P; Carmeliet P; Foidart JM; Noel A
Oncogene; 2004 Sep; 23(41):6986-90. PubMed ID: 15286708
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.
Czekay RP; Aertgeerts K; Curriden SA; Loskutoff DJ
J Cell Biol; 2003 Mar; 160(5):781-91. PubMed ID: 12615913
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin.
Lazar MH; Christensen PJ; Du M; Yu B; Subbotina NM; Hanson KE; Hansen JM; White ES; Simon RH; Sisson TH
Am J Respir Cell Mol Biol; 2004 Dec; 31(6):672-8. PubMed ID: 15308506
[TBL] [Abstract][Full Text] [Related]
15. uPA binding to PAI-1 induces corneal myofibroblast differentiation on vitronectin.
Wang L; Ly CM; Ko CY; Meyers EE; Lawrence DA; Bernstein AM
Invest Ophthalmol Vis Sci; 2012 Jul; 53(8):4765-75. PubMed ID: 22700714
[TBL] [Abstract][Full Text] [Related]
16. [Role of plasminogen activator inhibitor type 1 in tumor angiogenesis].
Bajou K; Devy L; Masson V; Albert V; Frankenne F; Noël A; Foidart JM
Therapie; 2001; 56(5):465-72. PubMed ID: 11806282
[TBL] [Abstract][Full Text] [Related]
17. Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in vitronectin.
De Lorenzi V; Sarra Ferraris GM; Madsen JB; Lupia M; Andreasen PA; Sidenius N
EMBO Rep; 2016 Jul; 17(7):982-98. PubMed ID: 27189837
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin.
Isogai C; Laug WE; Shimada H; Declerck PJ; Stins MF; Durden DL; Erdreich-Epstein A; DeClerck YA
Cancer Res; 2001 Jul; 61(14):5587-94. PubMed ID: 11454712
[TBL] [Abstract][Full Text] [Related]
19. Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system.
Stahl A; Mueller BM
Int J Cancer; 1997 Mar; 71(1):116-22. PubMed ID: 9096674
[TBL] [Abstract][Full Text] [Related]
20. A truncated plasminogen activator inhibitor-1 protein induces and inhibits angiostatin (kringles 1-3), a plasminogen cleavage product.
Mulligan-Kehoe MJ; Wagner R; Wieland C; Powell R
J Biol Chem; 2001 Mar; 276(11):8588-96. PubMed ID: 11113116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
